MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Monopar Therapeutics Inc (MNPR) is not a strong buy for a beginner, long-term investor at this time. The lack of significant positive financial performance, absence of recent news catalysts, and neutral trading trends suggest that the stock does not currently present a compelling long-term investment opportunity. The technical indicators and lack of proprietary trading signals further reinforce a hold recommendation.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral at 53.357, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 55, with resistance at 59.733 and support at 51.657. Overall, the technical indicators do not strongly support a buy decision.
Morgan Stanley's Overweight rating and $115 price target, citing the potential of ALXN1840 as a differentiated therapy for Wilson's disease, provide a positive long-term outlook.
No recent news or significant trading trends from hedge funds or insiders. Financial performance remains weak, with no revenue and negative net income. Stock trend analysis indicates a potential short-term decline (-1.97% in the next day, -3.65% in the next week).
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$3,437,601, which improved by 163.56% YoY but remains negative. EPS improved to -0.48, up 29.73% YoY, but still negative. Gross margin remains at 0%. Overall, the financials do not indicate strong growth or profitability.
Morgan Stanley initiated coverage with an Overweight rating and a $115 price target, citing the potential of ALXN1840 as a differentiated therapy for Wilson's disease. This suggests a positive long-term outlook but does not align with the current weak financials and trading sentiment.
